MBRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses...

Stats
Šios dienos apimtis	5 642.00
Vidutinė apimtis	109 247
Rinkos kapitalizacija	11.47M
EPS	$0 ( 2024-03-27 )
Kita pelno data	( $-3.59 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.340
ATR14	$0.0520 (1.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Foster Jonathan P.	Buy	28 986	Common Stock
2023-12-26	George Robert E.	Buy	14 493	Common Stock
2023-12-26	Klemp Walter V	Buy	188 404	Common Stock
2023-07-11	Klemp Walter V	Sell	13 204	Restricted Stock Units
2023-07-11	Klemp Walter V	Buy	13 204	Common Stock

INSIDER POWER
82.98
Last 98 transactions
Buy: 6 351 373 \| Sell: 471 392

Tūris Koreliacija

Ilgas: -0.18 (neutral)

Trumpas: -0.53 (weak negative)

Signal:(48.585) Neutral

Moleculin Biotech Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Moleculin Biotech Inc Koreliacija - Valiuta/Žaliavos

-0.20
( neutral )

-0.10
( neutral )

-0.09
( neutral )

-0.26
( neutral )

0.17
( neutral )

0.12
( neutral )

Moleculin Biotech Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2023
Pajamos:	$0
Bruto pelnas:	$-127 000 (0.00 %)
EPS:	$-15.07

FY	2022
Pajamos:	$0
Bruto pelnas:	$-222 000 (0.00 %)
EPS:	$-14.37

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$-164 000 (0.00 %)
EPS:	$-1.614

Financial Reports:

No articles found.

Moleculin Biotech Inc

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.